Bilayer 5-ALA and Hydroxychloroquine Tablet for COVID-19 Sequelae
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19, including hydroxychloroquine and chloroquine, do not effectively address the imbalance of porphyrins and free iron caused by SARS-CoV-2 infection, leading to severe sequelae such as blood clotting disorders and respiratory issues.
Innovation Solution
A stable pharmaceutical combination of hydroxychloroquine, chloroquine, and 5-aminolevulinic acid, or their salts, particularly zinc salts, is administered in a bilayer tablet form with immediate and sustained release profiles to balance porphyrin production and elimination, preventing excessive free iron circulation without causing acute porphyria symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxychloroquine and chloroquine are administered to treat SARS-CoV-2 infection, then viral replication is inhibited, but porphyrin imbalance and excessive free iron circulation occur leading to severe sequelae
Solution Approach 1:
The patent converts the harmful effect of porphyrin accumulation (which causes acute porphyria symptoms) into a beneficial therapeutic effect by using 5-ALA to deliberately increase porphyrin production. The combination of chloroquine/hydroxychloroquine with 5-ALA transforms the porphyrin imbalance caused by antiviral treatment into a therapeutic mechanism that eliminates excess free iron through controlled porphyrin synthesis, thereby treating both the viral infection and the iron-related sequelae
Solution Approach 2:
The patent merges two previously separate therapeutic approaches into a single combination treatment: (1) chloroquine/hydroxychloroquine for antiviral activity, and (2) 5-ALA for porphyrin production enhancement. This combination addresses both the viral replication and the porphyrin-iron imbalance simultaneously, converting a harmful side effect into a therapeutic benefit
2Quantity of substance
If 5-aminolevulinic acid is administered to increase porphyrin production, then free iron is eliminated, but acute porphyria symptoms may occur
Solution Approach 1:
The patent changes the dosage parameters of 5-ALA to a specific range (250-1600 mg) that is sufficient to increase porphyrin production and eliminate free iron but remains below the threshold that triggers acute porphyria symptoms. This parameter optimization allows the therapeutic effect while avoiding the harmful side effect
Solution Approach 2:
The patent uses chloroquine and hydroxychloroquine as intermediaries that modulate the effect of 5-ALA on porphyrin metabolism. These drugs interfere with porphyrin degradation pathways, creating a balanced system where 5-ALA increases production while the antimalarials prevent excessive accumulation, thereby avoiding acute porphyria symptoms
3Quantity of substance
If broad-spectrum antiviral drugs are used to reduce viral load, then RNAemia decreases, but immune evasion by SARS-CoV-2 is not effectively interfered with
Solution Approach 1:
The patent assigns multiple functions to the chloroquine/hydroxychloroquine component: (1) direct antiviral activity against SARS-CoV-2, (2) enhancement of 5-ALA-induced porphyrin production, and (3) interference with the virus-iron-porphyrin metabolic pathway. This multi-functionality addresses both viral replication and the underlying metabolic disruption, providing more comprehensive immunity interference than single-function antivirals
Data Source
AI summary
A bilayer composition for amelioriation of, or prophylaxis against, SARS-CoV-2 infection comprising a: (i) a first layer consisting of 250 mg to 1600 mg of 5-aminolevulinic acid (ALA), or salt thereof, and pharmaceutically acceptable excipients that allow for immediate release of the 5-aminolevulinic acid; (ii) a second layer consisting of hydroxychloroquine (HCQ), and/or a salt thereof, in a dose of 100 mg-1500 mg, or salt thereof, and at least one pharmaceutically acceptable excipient comprising a release modifier for sustained release of the hydroxychloroquine or chloroquine.